[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fMPm2Za5r-6e5lQRfYjTFupGYj-vxKOUUBFSb1CLxEgg":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":87,"rows":94},"Institut Paoli-Calmettes",[4],168,false,52,9,257242,21,116,[14,17,20,23,26,28,31,33],{"name":15,"count":16},"Breast Cancer",14,{"name":18,"count":19},"Acute Myeloid Leukemia",11,{"name":21,"count":22},"Myelodysplastic Syndromes",6,{"name":24,"count":25},"Prostate Cancer",5,{"name":27,"count":25},"Leukemia",{"name":29,"count":30},"Acute Leukemia",4,{"name":32,"count":30},"Cancer",{"name":34,"count":35},"Colorectal Adenoma",3,[37,42,47,52,57,62,67,72,77,82],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03515798","Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer","2022-08-22","Pembrolizumab",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04451200","Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning","2023-11","Busulfan",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT01985061","Evaluation of 3 Different Doses of IV Busulfan","2026-07-07","BX2",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT06055621","Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE","2026-07-08","Dasatinib",{"nctId":58,"briefTitle":59,"date":60,"intervention":61},"NCT05143970","A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors","2027-03","IPH5301 ALONE OR IN COMBINATION WITH CHEMOTHERAPY AND TRASTUZUMAB",{"nctId":63,"briefTitle":64,"date":65,"intervention":66},"NCT05986071","I\u002FII Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers","2027-04-01","M1774",{"nctId":68,"briefTitle":69,"date":70,"intervention":71},"NCT03597321","Early Prophylactic Donor Lymphocyte Infusion After Allo-HSCT for Patients With AML","2027-05","prophylactic donor lymphocyte",{"nctId":73,"briefTitle":74,"date":75,"intervention":76},"NCT04185272","Butyrophilins Role in Colon Cancer","2027-06-30","analysis of BTN and BTNL status",{"nctId":78,"briefTitle":79,"date":80,"intervention":81},"NCT05519670","A Phase 1b\u002F2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr","2027-09","Niraparib Oral Product",{"nctId":83,"briefTitle":84,"date":85,"intervention":86},"NCT06557421","De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients","2028-11-01","Venetoclax",[88,89,90,91,92,93],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[95,175,197,219,239,257,280,298,316,341,363,381,403,421,442,471,498,525,543,561,579,601,628,653,679,697,723,741,767,793,815,840,858,876,894,912,930,948,976,1001,1019,1037,1055,1078,1105,1128,1153,1179,1203,1226,1252,1276,1301,1327,1345,1372,1396,1419,1443,1467,1491,1517,1541,1570,1595,1619,1643,1670,1693,1717],{"intervention":96,"totalTrials":25,"cells":97},"busulfan",{"EARLY_PHASE1":98,"PHASE1":101,"PHASE2":103,"PHASE3":169,"PHASE4":171,"NA":173},{"trials":99,"activeCount":100},[],0,{"trials":102,"activeCount":100},[],{"trials":104,"activeCount":168,"soonestReadout":45},[105,115,131,144,160],{"nctId":43,"briefTitle":44,"status":106,"phases":107,"primaryCompletion":45,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":114},"NOT_YET_RECRUITING",[90],"2028-12","2020-11",82,[29,112,113],"Mielodysplasic Syndrome","Myeloproliferative Neoplasm",[46],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":123,"interventions":124},"NCT00840684","Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia","COMPLETED",[89,90],"2011-05","2009-01",135,[27],[125,96,126,127,128,129,130],"amsacrine","cytarabine","daunorubicin hydrochloride","laromustine","melphalan","mitoxantrone hydrochloride",{"nctId":132,"briefTitle":133,"status":118,"phases":134,"primaryCompletion":120,"start":135,"enrollment":110,"conditions":136,"interventions":141},"NCT00806767","Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer",[90],"2007-03",[137,27,138,139,21,140],"Chronic Myeloproliferative Disorders","Lymphoma","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Neoplasms",[142,96,143],"therapeutic immune globulin","fludarabine phosphate",{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"start":150,"enrollment":151,"conditions":152,"interventions":155},"NCT00740467","Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders","UNKNOWN",[90],"2010-01","2008-01",50,[153,27,138,139,154],"Graft Versus Host Disease","Precancerous Condition",[156,96,157,158,143,159],"anti-thymocyte globulin","cyclophosphamide","cyclosporine","mycophenolate mofetil",{"nctId":161,"briefTitle":162,"status":118,"phases":163,"primaryCompletion":120,"start":164,"enrollment":165,"conditions":166,"interventions":167},"NCT00802568","Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment",[90],"2007-04",48,[139],[156,96,143],1,{"trials":170,"activeCount":100},[],{"trials":172,"activeCount":100},[],{"trials":174,"activeCount":100},[],{"intervention":71,"totalTrials":168,"cells":176},{"EARLY_PHASE1":177,"PHASE1":179,"PHASE2":181,"PHASE3":191,"PHASE4":193,"NA":195},{"trials":178,"activeCount":100},[],{"trials":180,"activeCount":100},[],{"trials":182,"activeCount":168,"soonestReadout":70},[183],{"nctId":68,"briefTitle":69,"status":184,"phases":185,"primaryCompletion":70,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":190},"ACTIVE_NOT_RECRUITING",[90],"2028-05","2020-09-07",124,[18],[71],{"trials":192,"activeCount":100},[],{"trials":194,"activeCount":100},[],{"trials":196,"activeCount":100},[],{"intervention":56,"totalTrials":168,"cells":198},{"EARLY_PHASE1":199,"PHASE1":201,"PHASE2":203,"PHASE3":213,"PHASE4":215,"NA":217},{"trials":200,"activeCount":100},[],{"trials":202,"activeCount":100},[],{"trials":204,"activeCount":168,"soonestReadout":55},[205],{"nctId":53,"briefTitle":54,"status":206,"phases":207,"primaryCompletion":55,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":212},"RECRUITING",[90],"2027-10-31","2024-05-22",35,[18],[56],{"trials":214,"activeCount":100},[],{"trials":216,"activeCount":100},[],{"trials":218,"activeCount":100},[],{"intervention":86,"totalTrials":168,"cells":220},{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":233,"PHASE4":235,"NA":237},{"trials":222,"activeCount":100},[],{"trials":224,"activeCount":100},[],{"trials":226,"activeCount":168,"soonestReadout":85},[227],{"nctId":83,"briefTitle":84,"status":206,"phases":228,"primaryCompletion":85,"completion":85,"start":229,"enrollment":151,"conditions":230,"interventions":231},[90],"2026-02-04",[18],[86,232],"Azacitidine",{"trials":234,"activeCount":100},[],{"trials":236,"activeCount":100},[],{"trials":238,"activeCount":100},[],{"intervention":232,"totalTrials":168,"cells":240},{"EARLY_PHASE1":241,"PHASE1":243,"PHASE2":245,"PHASE3":251,"PHASE4":253,"NA":255},{"trials":242,"activeCount":100},[],{"trials":244,"activeCount":100},[],{"trials":246,"activeCount":168,"soonestReadout":85},[247],{"nctId":83,"briefTitle":84,"status":206,"phases":248,"primaryCompletion":85,"completion":85,"start":229,"enrollment":151,"conditions":249,"interventions":250},[90],[18],[86,232],{"trials":252,"activeCount":100},[],{"trials":254,"activeCount":100},[],{"trials":256,"activeCount":100},[],{"intervention":51,"totalTrials":168,"cells":258},{"EARLY_PHASE1":259,"PHASE1":261,"PHASE2":263,"PHASE3":274,"PHASE4":276,"NA":278},{"trials":260,"activeCount":100},[],{"trials":262,"activeCount":100},[],{"trials":264,"activeCount":168,"soonestReadout":50},[265],{"nctId":48,"briefTitle":49,"status":184,"phases":266,"primaryCompletion":50,"completion":50,"start":267,"enrollment":268,"conditions":269,"interventions":271},[90],"2013-12",177,[270,18],"Myelodysplastic Syndrome",[51,272,273],"BX3","BX4-Suspended",{"trials":275,"activeCount":100},[],{"trials":277,"activeCount":100},[],{"trials":279,"activeCount":100},[],{"intervention":272,"totalTrials":168,"cells":281},{"EARLY_PHASE1":282,"PHASE1":284,"PHASE2":286,"PHASE3":292,"PHASE4":294,"NA":296},{"trials":283,"activeCount":100},[],{"trials":285,"activeCount":100},[],{"trials":287,"activeCount":168,"soonestReadout":50},[288],{"nctId":48,"briefTitle":49,"status":184,"phases":289,"primaryCompletion":50,"completion":50,"start":267,"enrollment":268,"conditions":290,"interventions":291},[90],[270,18],[51,272,273],{"trials":293,"activeCount":100},[],{"trials":295,"activeCount":100},[],{"trials":297,"activeCount":100},[],{"intervention":273,"totalTrials":168,"cells":299},{"EARLY_PHASE1":300,"PHASE1":302,"PHASE2":304,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":301,"activeCount":100},[],{"trials":303,"activeCount":100},[],{"trials":305,"activeCount":168,"soonestReadout":50},[306],{"nctId":48,"briefTitle":49,"status":184,"phases":307,"primaryCompletion":50,"completion":50,"start":267,"enrollment":268,"conditions":308,"interventions":309},[90],[270,18],[51,272,273],{"trials":311,"activeCount":100},[],{"trials":313,"activeCount":100},[],{"trials":315,"activeCount":100},[],{"intervention":317,"totalTrials":168,"cells":318},"fludarabine and treosulfan",{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":335,"PHASE4":337,"NA":339},{"trials":320,"activeCount":100},[],{"trials":322,"activeCount":100},[],{"trials":324,"activeCount":168,"soonestReadout":329},[325],{"nctId":326,"briefTitle":327,"status":106,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":334},"NCT07598110","FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND\u002FOR FRAIL PATIENTS WITH AML",[90],"2030-10-10","2031-02-10","2026-10-10",77,[18],[317],{"trials":336,"activeCount":100},[],{"trials":338,"activeCount":100},[],{"trials":340,"activeCount":100},[],{"intervention":41,"totalTrials":168,"cells":342},{"EARLY_PHASE1":343,"PHASE1":345,"PHASE2":347,"PHASE3":357,"PHASE4":359,"NA":361},{"trials":344,"activeCount":100},[],{"trials":346,"activeCount":100},[],{"trials":348,"activeCount":168,"soonestReadout":40},[349],{"nctId":38,"briefTitle":39,"status":184,"phases":350,"primaryCompletion":40,"completion":351,"start":352,"enrollment":8,"conditions":353,"interventions":355},[90],"2027-08-22","2018-08-29",[354],"Inflammatory Breast Cancer",[41,356],"neoadjuvant EC-paclitaxel chemotherapy",{"trials":358,"activeCount":100},[],{"trials":360,"activeCount":100},[],{"trials":362,"activeCount":100},[],{"intervention":356,"totalTrials":168,"cells":364},{"EARLY_PHASE1":365,"PHASE1":367,"PHASE2":369,"PHASE3":375,"PHASE4":377,"NA":379},{"trials":366,"activeCount":100},[],{"trials":368,"activeCount":100},[],{"trials":370,"activeCount":168,"soonestReadout":40},[371],{"nctId":38,"briefTitle":39,"status":184,"phases":372,"primaryCompletion":40,"completion":351,"start":352,"enrollment":8,"conditions":373,"interventions":374},[90],[354],[41,356],{"trials":376,"activeCount":100},[],{"trials":378,"activeCount":100},[],{"trials":380,"activeCount":100},[],{"intervention":66,"totalTrials":168,"cells":382},{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":397,"PHASE4":399,"NA":401},{"trials":384,"activeCount":100},[],{"trials":386,"activeCount":100},[],{"trials":388,"activeCount":168,"soonestReadout":65},[389],{"nctId":63,"briefTitle":64,"status":106,"phases":390,"primaryCompletion":65,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":395},[89,90],"2027-10-15","2024-05-01",57,[15],[66,396],"Fulvestrant",{"trials":398,"activeCount":100},[],{"trials":400,"activeCount":100},[],{"trials":402,"activeCount":100},[],{"intervention":396,"totalTrials":168,"cells":404},{"EARLY_PHASE1":405,"PHASE1":407,"PHASE2":409,"PHASE3":415,"PHASE4":417,"NA":419},{"trials":406,"activeCount":100},[],{"trials":408,"activeCount":100},[],{"trials":410,"activeCount":168,"soonestReadout":65},[411],{"nctId":63,"briefTitle":64,"status":106,"phases":412,"primaryCompletion":65,"completion":391,"start":392,"enrollment":393,"conditions":413,"interventions":414},[89,90],[15],[66,396],{"trials":416,"activeCount":100},[],{"trials":418,"activeCount":100},[],{"trials":420,"activeCount":100},[],{"intervention":81,"totalTrials":168,"cells":422},{"EARLY_PHASE1":423,"PHASE1":425,"PHASE2":427,"PHASE3":436,"PHASE4":438,"NA":440},{"trials":424,"activeCount":100},[],{"trials":426,"activeCount":100},[],{"trials":428,"activeCount":168,"soonestReadout":80},[429],{"nctId":78,"briefTitle":79,"status":106,"phases":430,"primaryCompletion":80,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":435},[89,90],"2027-12","2023-03",72,[15],[81],{"trials":437,"activeCount":100},[],{"trials":439,"activeCount":100},[],{"trials":441,"activeCount":100},[],{"intervention":61,"totalTrials":168,"cells":443},{"EARLY_PHASE1":444,"PHASE1":446,"PHASE2":463,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":445,"activeCount":100},[],{"trials":447,"activeCount":168,"soonestReadout":60},[448],{"nctId":58,"briefTitle":59,"status":206,"phases":449,"primaryCompletion":60,"completion":60,"start":450,"enrollment":451,"conditions":452,"interventions":462},[89],"2022-01-21",27,[453,454,455,456,457,458,459,460,461],"Metastatic Cancer","Metastatic Breast Cancer","Metastatic Pancreatic Cancer","Metastatic Gastric Cancer","Metastatic Lung Cancer","Metastatic Ovary Cancer","Oesophageal Cancer","Endometrial Cancer","Advanced Solid Tumor",[61],{"trials":464,"activeCount":100},[],{"trials":466,"activeCount":100},[],{"trials":468,"activeCount":100},[],{"trials":470,"activeCount":100},[],{"intervention":472,"totalTrials":168,"cells":473},"mFOLFIRINOX",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":475,"activeCount":100},[],{"trials":477,"activeCount":100},[],{"trials":479,"activeCount":100},[],{"trials":481,"activeCount":100},[],{"trials":483,"activeCount":100},[],{"trials":485,"activeCount":168,"soonestReadout":490},[486],{"nctId":487,"briefTitle":488,"status":106,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":493,"conditions":494,"interventions":497},"NCT07592819","A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC)",[93],"2030-05","2031-11","2026-05",367,[495,496],"Pancreas Adenocarcinoma (MSI-H)","Pancreatic Cancer Resectable",[472],{"intervention":499,"totalTrials":168,"cells":500},"Pre-treatment biopsy",{"EARLY_PHASE1":501,"PHASE1":503,"PHASE2":505,"PHASE3":507,"PHASE4":509,"NA":511},{"trials":502,"activeCount":100},[],{"trials":504,"activeCount":100},[],{"trials":506,"activeCount":100},[],{"trials":508,"activeCount":100},[],{"trials":510,"activeCount":100},[],{"trials":512,"activeCount":168,"soonestReadout":85},[513],{"nctId":514,"briefTitle":515,"status":184,"phases":516,"primaryCompletion":85,"completion":85,"start":517,"enrollment":518,"conditions":519,"interventions":521},"NCT05529862","Trans-RosaLEE Study: a Biomarker-directed, Translational Study",[93],"2023-06-20",115,[520],"Advanced or Metastatic Breast Cancer (BC)",[499,522,523,524],"Post treatment biopsy","Pre treatment blood sampling","Post treatment blood sampling",{"intervention":522,"totalTrials":168,"cells":526},{"EARLY_PHASE1":527,"PHASE1":529,"PHASE2":531,"PHASE3":533,"PHASE4":535,"NA":537},{"trials":528,"activeCount":100},[],{"trials":530,"activeCount":100},[],{"trials":532,"activeCount":100},[],{"trials":534,"activeCount":100},[],{"trials":536,"activeCount":100},[],{"trials":538,"activeCount":168,"soonestReadout":85},[539],{"nctId":514,"briefTitle":515,"status":184,"phases":540,"primaryCompletion":85,"completion":85,"start":517,"enrollment":518,"conditions":541,"interventions":542},[93],[520],[499,522,523,524],{"intervention":523,"totalTrials":168,"cells":544},{"EARLY_PHASE1":545,"PHASE1":547,"PHASE2":549,"PHASE3":551,"PHASE4":553,"NA":555},{"trials":546,"activeCount":100},[],{"trials":548,"activeCount":100},[],{"trials":550,"activeCount":100},[],{"trials":552,"activeCount":100},[],{"trials":554,"activeCount":100},[],{"trials":556,"activeCount":168,"soonestReadout":85},[557],{"nctId":514,"briefTitle":515,"status":184,"phases":558,"primaryCompletion":85,"completion":85,"start":517,"enrollment":518,"conditions":559,"interventions":560},[93],[520],[499,522,523,524],{"intervention":524,"totalTrials":168,"cells":562},{"EARLY_PHASE1":563,"PHASE1":565,"PHASE2":567,"PHASE3":569,"PHASE4":571,"NA":573},{"trials":564,"activeCount":100},[],{"trials":566,"activeCount":100},[],{"trials":568,"activeCount":100},[],{"trials":570,"activeCount":100},[],{"trials":572,"activeCount":100},[],{"trials":574,"activeCount":168,"soonestReadout":85},[575],{"nctId":514,"briefTitle":515,"status":184,"phases":576,"primaryCompletion":85,"completion":85,"start":517,"enrollment":518,"conditions":577,"interventions":578},[93],[520],[499,522,523,524],{"intervention":76,"totalTrials":168,"cells":580},{"EARLY_PHASE1":581,"PHASE1":583,"PHASE2":585,"PHASE3":587,"PHASE4":589,"NA":591},{"trials":582,"activeCount":100},[],{"trials":584,"activeCount":100},[],{"trials":586,"activeCount":100},[],{"trials":588,"activeCount":100},[],{"trials":590,"activeCount":100},[],{"trials":592,"activeCount":168,"soonestReadout":75},[593],{"nctId":73,"briefTitle":74,"status":206,"phases":594,"primaryCompletion":75,"completion":595,"start":596,"enrollment":597,"conditions":598,"interventions":600},[93],"2028-06","2020-06-30",200,[599],"Colonic Cancer",[76],{"intervention":602,"totalTrials":168,"cells":603},"immune-checkpoint inhibitors therapies",{"EARLY_PHASE1":604,"PHASE1":606,"PHASE2":608,"PHASE3":610,"PHASE4":612,"NA":626},{"trials":605,"activeCount":100},[],{"trials":607,"activeCount":100},[],{"trials":609,"activeCount":100},[],{"trials":611,"activeCount":100},[],{"trials":613,"activeCount":100},[614],{"nctId":615,"briefTitle":616,"status":617,"phases":618,"primaryCompletion":619,"completion":619,"start":620,"enrollment":621,"conditions":622,"interventions":625},"NCT03673332","Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies","TERMINATED",[92],"2024-10-29","2019-10-16",40,[623,624],"Advanced or Metastatic Melanoma","Advanced or Metastatic NSCLC",[602],{"trials":627,"activeCount":100},[],{"intervention":629,"totalTrials":168,"cells":630},"Neoadjuvant chemotherapy",{"EARLY_PHASE1":631,"PHASE1":633,"PHASE2":635,"PHASE3":637,"PHASE4":649,"NA":651},{"trials":632,"activeCount":100},[],{"trials":634,"activeCount":100},[],{"trials":636,"activeCount":100},[],{"trials":638,"activeCount":100},[639],{"nctId":640,"briefTitle":641,"status":118,"phases":642,"primaryCompletion":643,"completion":643,"start":644,"enrollment":645,"conditions":646,"interventions":648},"NCT01521702","NEOadjuvant Gemcitabine\u002FOxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer",[91],"2015-02","2011-12",2,[647],"Pancreas Cancer",[629],{"trials":650,"activeCount":100},[],{"trials":652,"activeCount":100},[],{"intervention":654,"totalTrials":168,"cells":655},"Ropivacaine",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":662,"PHASE4":675,"NA":677},{"trials":657,"activeCount":100},[],{"trials":659,"activeCount":100},[],{"trials":661,"activeCount":100},[],{"trials":663,"activeCount":100},[664],{"nctId":665,"briefTitle":666,"status":617,"phases":667,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":672,"interventions":673},"NCT02525211","Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment",[91],"2017-04-21","2017-10","2012-10",59,[15],[654,674],"physiological saline",{"trials":676,"activeCount":100},[],{"trials":678,"activeCount":100},[],{"intervention":674,"totalTrials":168,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":693,"NA":695},{"trials":682,"activeCount":100},[],{"trials":684,"activeCount":100},[],{"trials":686,"activeCount":100},[],{"trials":688,"activeCount":100},[689],{"nctId":665,"briefTitle":666,"status":617,"phases":690,"primaryCompletion":668,"completion":669,"start":670,"enrollment":671,"conditions":691,"interventions":692},[91],[15],[654,674],{"trials":694,"activeCount":100},[],{"trials":696,"activeCount":100},[],{"intervention":698,"totalTrials":168,"cells":699},"gemcitabine hydrochloride",{"EARLY_PHASE1":700,"PHASE1":702,"PHASE2":704,"PHASE3":706,"PHASE4":719,"NA":721},{"trials":701,"activeCount":100},[],{"trials":703,"activeCount":100},[],{"trials":705,"activeCount":100},[],{"trials":707,"activeCount":100},[708],{"nctId":709,"briefTitle":710,"status":147,"phases":711,"primaryCompletion":712,"start":713,"enrollment":714,"conditions":715,"interventions":717},"NCT00541021","Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",[91],"2010-12","2006-12",104,[716],"Pancreatic Cancer",[698,718],"sorafenib tosylate",{"trials":720,"activeCount":100},[],{"trials":722,"activeCount":100},[],{"intervention":718,"totalTrials":168,"cells":724},{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":737,"NA":739},{"trials":726,"activeCount":100},[],{"trials":728,"activeCount":100},[],{"trials":730,"activeCount":100},[],{"trials":732,"activeCount":100},[733],{"nctId":709,"briefTitle":710,"status":147,"phases":734,"primaryCompletion":712,"start":713,"enrollment":714,"conditions":735,"interventions":736},[91],[716],[698,718],{"trials":738,"activeCount":100},[],{"trials":740,"activeCount":100},[],{"intervention":742,"totalTrials":168,"cells":743},"Allogeneic (Allo) hematopoietic stem cell transplantation",{"EARLY_PHASE1":744,"PHASE1":746,"PHASE2":748,"PHASE3":750,"PHASE4":763,"NA":765},{"trials":745,"activeCount":100},[],{"trials":747,"activeCount":100},[],{"trials":749,"activeCount":100},[],{"trials":751,"activeCount":100},[752],{"nctId":753,"briefTitle":754,"status":118,"phases":755,"primaryCompletion":756,"completion":757,"start":758,"enrollment":759,"conditions":760,"interventions":762},"NCT02623309","Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients",[91],"2021-02-02","2021-03-12","2016-02-23",108,[761],"Hematologic Neoplasms",[742],{"trials":764,"activeCount":100},[],{"trials":766,"activeCount":100},[],{"intervention":143,"totalTrials":35,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":787,"PHASE4":789,"NA":791},{"trials":770,"activeCount":100},[],{"trials":772,"activeCount":100},[],{"trials":774,"activeCount":100},[775,779,783],{"nctId":132,"briefTitle":133,"status":118,"phases":776,"primaryCompletion":120,"start":135,"enrollment":110,"conditions":777,"interventions":778},[90],[137,27,138,139,21,140],[142,96,143],{"nctId":145,"briefTitle":146,"status":147,"phases":780,"primaryCompletion":149,"start":150,"enrollment":151,"conditions":781,"interventions":782},[90],[153,27,138,139,154],[156,96,157,158,143,159],{"nctId":161,"briefTitle":162,"status":118,"phases":784,"primaryCompletion":120,"start":164,"enrollment":165,"conditions":785,"interventions":786},[90],[139],[156,96,143],{"trials":788,"activeCount":100},[],{"trials":790,"activeCount":100},[],{"trials":792,"activeCount":100},[],{"intervention":156,"totalTrials":645,"cells":794},{"EARLY_PHASE1":795,"PHASE1":797,"PHASE2":799,"PHASE3":809,"PHASE4":811,"NA":813},{"trials":796,"activeCount":100},[],{"trials":798,"activeCount":100},[],{"trials":800,"activeCount":100},[801,805],{"nctId":145,"briefTitle":146,"status":147,"phases":802,"primaryCompletion":149,"start":150,"enrollment":151,"conditions":803,"interventions":804},[90],[153,27,138,139,154],[156,96,157,158,143,159],{"nctId":161,"briefTitle":162,"status":118,"phases":806,"primaryCompletion":120,"start":164,"enrollment":165,"conditions":807,"interventions":808},[90],[139],[156,96,143],{"trials":810,"activeCount":100},[],{"trials":812,"activeCount":100},[],{"trials":814,"activeCount":100},[],{"intervention":816,"totalTrials":168,"cells":817},"LY2780301 + paclitaxel",{"EARLY_PHASE1":818,"PHASE1":820,"PHASE2":822,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":819,"activeCount":100},[],{"trials":821,"activeCount":100},[],{"trials":823,"activeCount":100},[824],{"nctId":825,"briefTitle":826,"status":617,"phases":827,"primaryCompletion":828,"completion":829,"start":830,"enrollment":831,"conditions":832,"interventions":833},"NCT01980277","Phase Ib\u002FII Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer",[89,90],"2017-05","2018-12-12","2014-01",68,[15],[816],{"trials":835,"activeCount":100},[],{"trials":837,"activeCount":100},[],{"trials":839,"activeCount":100},[],{"intervention":125,"totalTrials":168,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":843,"activeCount":100},[],{"trials":845,"activeCount":100},[],{"trials":847,"activeCount":100},[848],{"nctId":116,"briefTitle":117,"status":118,"phases":849,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":850,"interventions":851},[89,90],[27],[125,96,126,127,128,129,130],{"trials":853,"activeCount":100},[],{"trials":855,"activeCount":100},[],{"trials":857,"activeCount":100},[],{"intervention":127,"totalTrials":168,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":861,"activeCount":100},[],{"trials":863,"activeCount":100},[],{"trials":865,"activeCount":100},[866],{"nctId":116,"briefTitle":117,"status":118,"phases":867,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":868,"interventions":869},[89,90],[27],[125,96,126,127,128,129,130],{"trials":871,"activeCount":100},[],{"trials":873,"activeCount":100},[],{"trials":875,"activeCount":100},[],{"intervention":128,"totalTrials":168,"cells":877},{"EARLY_PHASE1":878,"PHASE1":880,"PHASE2":882,"PHASE3":888,"PHASE4":890,"NA":892},{"trials":879,"activeCount":100},[],{"trials":881,"activeCount":100},[],{"trials":883,"activeCount":100},[884],{"nctId":116,"briefTitle":117,"status":118,"phases":885,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":886,"interventions":887},[89,90],[27],[125,96,126,127,128,129,130],{"trials":889,"activeCount":100},[],{"trials":891,"activeCount":100},[],{"trials":893,"activeCount":100},[],{"intervention":129,"totalTrials":168,"cells":895},{"EARLY_PHASE1":896,"PHASE1":898,"PHASE2":900,"PHASE3":906,"PHASE4":908,"NA":910},{"trials":897,"activeCount":100},[],{"trials":899,"activeCount":100},[],{"trials":901,"activeCount":100},[902],{"nctId":116,"briefTitle":117,"status":118,"phases":903,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":904,"interventions":905},[89,90],[27],[125,96,126,127,128,129,130],{"trials":907,"activeCount":100},[],{"trials":909,"activeCount":100},[],{"trials":911,"activeCount":100},[],{"intervention":130,"totalTrials":168,"cells":913},{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":915,"activeCount":100},[],{"trials":917,"activeCount":100},[],{"trials":919,"activeCount":100},[920],{"nctId":116,"briefTitle":117,"status":118,"phases":921,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":922,"interventions":923},[89,90],[27],[125,96,126,127,128,129,130],{"trials":925,"activeCount":100},[],{"trials":927,"activeCount":100},[],{"trials":929,"activeCount":100},[],{"intervention":142,"totalTrials":168,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":933,"activeCount":100},[],{"trials":935,"activeCount":100},[],{"trials":937,"activeCount":100},[938],{"nctId":132,"briefTitle":133,"status":118,"phases":939,"primaryCompletion":120,"start":135,"enrollment":110,"conditions":940,"interventions":941},[90],[137,27,138,139,21,140],[142,96,143],{"trials":943,"activeCount":100},[],{"trials":945,"activeCount":100},[],{"trials":947,"activeCount":100},[],{"intervention":949,"totalTrials":168,"cells":950},"reduced intensity conditionings",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":970,"PHASE4":972,"NA":974},{"trials":952,"activeCount":100},[],{"trials":954,"activeCount":100},[],{"trials":956,"activeCount":100},[957],{"nctId":958,"briefTitle":959,"status":118,"phases":960,"primaryCompletion":961,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":969},"NCT00894049","A Study Comparing Non Myeloablative (Flu-TBI) and Reduced Intensity (FLU-BU-ATG) Conditioning in Allogenic Transplantation",[90],"2013-02","2002-11",148,[965,966,967,968],"Allograft","Allogeneic Cell Transplantaion","Hematological Malignancy","Solid Tumor",[949],{"trials":971,"activeCount":100},[],{"trials":973,"activeCount":100},[],{"trials":975,"activeCount":100},[],{"intervention":977,"totalTrials":168,"cells":978},"Lenalidomide\u002FRituximab",{"EARLY_PHASE1":979,"PHASE1":981,"PHASE2":983,"PHASE3":995,"PHASE4":997,"NA":999},{"trials":980,"activeCount":100},[],{"trials":982,"activeCount":100},[],{"trials":984,"activeCount":100},[985],{"nctId":986,"briefTitle":987,"status":118,"phases":988,"primaryCompletion":669,"completion":989,"start":990,"enrollment":991,"conditions":992,"interventions":994},"NCT01939327","Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma",[90],"2020-01","2013-09",34,[993],"Non-Hodgkin Lymphoma",[977],{"trials":996,"activeCount":100},[],{"trials":998,"activeCount":100},[],{"trials":1000,"activeCount":100},[],{"intervention":157,"totalTrials":168,"cells":1002},{"EARLY_PHASE1":1003,"PHASE1":1005,"PHASE2":1007,"PHASE3":1013,"PHASE4":1015,"NA":1017},{"trials":1004,"activeCount":100},[],{"trials":1006,"activeCount":100},[],{"trials":1008,"activeCount":100},[1009],{"nctId":145,"briefTitle":146,"status":147,"phases":1010,"primaryCompletion":149,"start":150,"enrollment":151,"conditions":1011,"interventions":1012},[90],[153,27,138,139,154],[156,96,157,158,143,159],{"trials":1014,"activeCount":100},[],{"trials":1016,"activeCount":100},[],{"trials":1018,"activeCount":100},[],{"intervention":158,"totalTrials":168,"cells":1020},{"EARLY_PHASE1":1021,"PHASE1":1023,"PHASE2":1025,"PHASE3":1031,"PHASE4":1033,"NA":1035},{"trials":1022,"activeCount":100},[],{"trials":1024,"activeCount":100},[],{"trials":1026,"activeCount":100},[1027],{"nctId":145,"briefTitle":146,"status":147,"phases":1028,"primaryCompletion":149,"start":150,"enrollment":151,"conditions":1029,"interventions":1030},[90],[153,27,138,139,154],[156,96,157,158,143,159],{"trials":1032,"activeCount":100},[],{"trials":1034,"activeCount":100},[],{"trials":1036,"activeCount":100},[],{"intervention":159,"totalTrials":168,"cells":1038},{"EARLY_PHASE1":1039,"PHASE1":1041,"PHASE2":1043,"PHASE3":1049,"PHASE4":1051,"NA":1053},{"trials":1040,"activeCount":100},[],{"trials":1042,"activeCount":100},[],{"trials":1044,"activeCount":100},[1045],{"nctId":145,"briefTitle":146,"status":147,"phases":1046,"primaryCompletion":149,"start":150,"enrollment":151,"conditions":1047,"interventions":1048},[90],[153,27,138,139,154],[156,96,157,158,143,159],{"trials":1050,"activeCount":100},[],{"trials":1052,"activeCount":100},[],{"trials":1054,"activeCount":100},[],{"intervention":1056,"totalTrials":168,"cells":1057},"BKM120 + lapatinib",{"EARLY_PHASE1":1058,"PHASE1":1060,"PHASE2":1062,"PHASE3":1072,"PHASE4":1074,"NA":1076},{"trials":1059,"activeCount":100},[],{"trials":1061,"activeCount":100},[],{"trials":1063,"activeCount":100},[1064],{"nctId":1065,"briefTitle":1066,"status":617,"phases":1067,"primaryCompletion":1068,"completion":1068,"start":644,"enrollment":1069,"conditions":1070,"interventions":1071},"NCT01589861","Safety and Efficacy of BKM120 and Lapatinib in HER2+\u002FPI3K-activated, Trastuzumab-resistant Advanced Breast Cancer",[89,90],"2017-10-10",24,[15],[1056],{"trials":1073,"activeCount":100},[],{"trials":1075,"activeCount":100},[],{"trials":1077,"activeCount":100},[],{"intervention":1079,"totalTrials":168,"cells":1080},"Naloxégol oxalate",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1099,"PHASE4":1101,"NA":1103},{"trials":1082,"activeCount":100},[],{"trials":1084,"activeCount":100},[],{"trials":1086,"activeCount":100},[1087],{"nctId":1088,"briefTitle":1089,"status":147,"phases":1090,"primaryCompletion":1091,"completion":1092,"start":1093,"enrollment":1094,"conditions":1095,"interventions":1098},"NCT04219046","Evaluation of Naloxegol in the Prevention of POI After Cystectomy",[90],"2022-09","2022-12","2021-03",102,[1096,1097],"Bladder Cancer","Cystostomy; Complications",[1079],{"trials":1100,"activeCount":100},[],{"trials":1102,"activeCount":100},[],{"trials":1104,"activeCount":100},[],{"intervention":1106,"totalTrials":168,"cells":1107},"Rituximab",{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1122,"PHASE4":1124,"NA":1126},{"trials":1109,"activeCount":100},[],{"trials":1111,"activeCount":100},[],{"trials":1113,"activeCount":100},[1114],{"nctId":1115,"briefTitle":1116,"status":147,"phases":1117,"primaryCompletion":1118,"completion":1118,"start":644,"enrollment":210,"conditions":1119,"interventions":1121},"NCT01521689","Tolerance and Efficacy of Subcutanous Low Doses Rituximab for CLL Consolidation Treatment",[90],"2015-06",[1120],"Chronic Lymphocytic Leukemia",[1106],{"trials":1123,"activeCount":100},[],{"trials":1125,"activeCount":100},[],{"trials":1127,"activeCount":100},[],{"intervention":1129,"totalTrials":168,"cells":1130},"Chemotherapy",{"EARLY_PHASE1":1131,"PHASE1":1133,"PHASE2":1135,"PHASE3":1147,"PHASE4":1149,"NA":1151},{"trials":1132,"activeCount":100},[],{"trials":1134,"activeCount":100},[],{"trials":1136,"activeCount":100},[1137],{"nctId":1138,"briefTitle":1139,"status":147,"phases":1140,"primaryCompletion":1141,"completion":1142,"start":1143,"enrollment":1144,"conditions":1145,"interventions":1146},"NCT02679040","Histological Response Rate After Mastectomy and Immediate Breast Reconstruction at the End of Neoadjuvant Chemotherapy and Radiotherapy",[90],"2021-03-29","2025-02","2016-01-27",101,[15],[1129],{"trials":1148,"activeCount":100},[],{"trials":1150,"activeCount":100},[],{"trials":1152,"activeCount":100},[],{"intervention":1154,"totalTrials":168,"cells":1155},"Allogeneic transplant conditioning",{"EARLY_PHASE1":1156,"PHASE1":1158,"PHASE2":1160,"PHASE3":1173,"PHASE4":1175,"NA":1177},{"trials":1157,"activeCount":100},[],{"trials":1159,"activeCount":100},[],{"trials":1161,"activeCount":100},[1162],{"nctId":1163,"briefTitle":1164,"status":118,"phases":1165,"primaryCompletion":1166,"completion":1167,"start":1168,"enrollment":1169,"conditions":1170,"interventions":1172},"NCT02483325","Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases",[90],"2018-03","2020-03","2014-09",33,[1171],"Hematological Diseases",[1154],{"trials":1174,"activeCount":100},[],{"trials":1176,"activeCount":100},[],{"trials":1178,"activeCount":100},[],{"intervention":1180,"totalTrials":168,"cells":1181},"Eribulin",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1197,"PHASE4":1199,"NA":1201},{"trials":1183,"activeCount":100},[],{"trials":1185,"activeCount":100},[],{"trials":1187,"activeCount":100},[1188],{"nctId":1189,"briefTitle":1190,"status":1191,"phases":1192,"primaryCompletion":1193,"completion":1193,"start":1194,"enrollment":100,"conditions":1195,"interventions":1196},"NCT03637868","Eribulin in Brain Metastases From HER2-negative Breast Cancer","WITHDRAWN",[90],"2020-04-14","2019-02-26",[454],[1180],{"trials":1198,"activeCount":100},[],{"trials":1200,"activeCount":100},[],{"trials":1202,"activeCount":100},[],{"intervention":1204,"totalTrials":168,"cells":1205},"Thymoglobulin Injectable Product",{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1220,"PHASE4":1222,"NA":1224},{"trials":1207,"activeCount":100},[],{"trials":1209,"activeCount":100},[],{"trials":1211,"activeCount":100},[1212],{"nctId":1213,"briefTitle":1214,"status":147,"phases":1215,"primaryCompletion":1216,"completion":1216,"start":1217,"enrollment":451,"conditions":1218,"interventions":1219},"NCT06066255","PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM",[90],"2026-03-31","2024-03-31",[967],[1204],{"trials":1221,"activeCount":100},[],{"trials":1223,"activeCount":100},[],{"trials":1225,"activeCount":100},[],{"intervention":1227,"totalTrials":168,"cells":1228},"Avelumab",{"EARLY_PHASE1":1229,"PHASE1":1231,"PHASE2":1233,"PHASE3":1246,"PHASE4":1248,"NA":1250},{"trials":1230,"activeCount":100},[],{"trials":1232,"activeCount":100},[],{"trials":1234,"activeCount":100},[1235],{"nctId":1236,"briefTitle":1237,"status":147,"phases":1238,"primaryCompletion":1239,"completion":1240,"start":1241,"enrollment":1242,"conditions":1243,"interventions":1245},"NCT03950362","Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer",[90],"2023-06-15","2024-06-15","2020-06-15",67,[1244],"Non-muscle-invasive Bladder Cancer",[1227],{"trials":1247,"activeCount":100},[],{"trials":1249,"activeCount":100},[],{"trials":1251,"activeCount":100},[],{"intervention":1253,"totalTrials":168,"cells":1254},"recwt1-A10+AS01B",{"EARLY_PHASE1":1255,"PHASE1":1257,"PHASE2":1259,"PHASE3":1270,"PHASE4":1272,"NA":1274},{"trials":1256,"activeCount":100},[],{"trials":1258,"activeCount":100},[],{"trials":1260,"activeCount":100},[1261],{"nctId":1262,"briefTitle":1263,"status":118,"phases":1264,"primaryCompletion":1265,"completion":1265,"start":1266,"enrollment":645,"conditions":1267,"interventions":1269},"NCT01819558","Phase I\u002FII Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy",[89,90],"2015-03","2013-03",[18,1268,270],"Chronic Myeloid Leukemia",[1253],{"trials":1271,"activeCount":100},[],{"trials":1273,"activeCount":100},[],{"trials":1275,"activeCount":100},[],{"intervention":1277,"totalTrials":168,"cells":1278},"Apalutamide",{"EARLY_PHASE1":1279,"PHASE1":1281,"PHASE2":1283,"PHASE3":1295,"PHASE4":1297,"NA":1299},{"trials":1280,"activeCount":100},[],{"trials":1282,"activeCount":100},[],{"trials":1284,"activeCount":100},[1285],{"nctId":1286,"briefTitle":1287,"status":118,"phases":1288,"primaryCompletion":1289,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT03088124","Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer",[90],"2024-10-08","2017-04-28",93,[1293],"Low Risk Prostate Cancer",[1277],{"trials":1296,"activeCount":100},[],{"trials":1298,"activeCount":100},[],{"trials":1300,"activeCount":100},[],{"intervention":1302,"totalTrials":168,"cells":1303},"bevacizumab",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1321,"PHASE4":1323,"NA":1325},{"trials":1305,"activeCount":100},[],{"trials":1307,"activeCount":100},[],{"trials":1309,"activeCount":100},[1310],{"nctId":1311,"briefTitle":1312,"status":118,"phases":1313,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1319},"NCT01190345","Anti Cancer Stem Cell Activity of Pre-operative Bevacizumab and Chemotherapy in Breast Cancer",[90],"2012-07-24","2017-10-06","2010-05",75,[15],[1302,1320],"no bevacizumab",{"trials":1322,"activeCount":100},[],{"trials":1324,"activeCount":100},[],{"trials":1326,"activeCount":100},[],{"intervention":1320,"totalTrials":168,"cells":1328},{"EARLY_PHASE1":1329,"PHASE1":1331,"PHASE2":1333,"PHASE3":1339,"PHASE4":1341,"NA":1343},{"trials":1330,"activeCount":100},[],{"trials":1332,"activeCount":100},[],{"trials":1334,"activeCount":100},[1335],{"nctId":1311,"briefTitle":1312,"status":118,"phases":1336,"primaryCompletion":1314,"completion":1315,"start":1316,"enrollment":1317,"conditions":1337,"interventions":1338},[90],[15],[1302,1320],{"trials":1340,"activeCount":100},[],{"trials":1342,"activeCount":100},[],{"trials":1344,"activeCount":100},[],{"intervention":1346,"totalTrials":168,"cells":1347},"Fludarabine-Cladribine-Busulfan conditioning regimen",{"EARLY_PHASE1":1348,"PHASE1":1350,"PHASE2":1364,"PHASE3":1366,"PHASE4":1368,"NA":1370},{"trials":1349,"activeCount":100},[],{"trials":1351,"activeCount":100},[1352],{"nctId":1353,"briefTitle":1354,"status":147,"phases":1355,"primaryCompletion":1356,"completion":1357,"start":1358,"enrollment":1359,"conditions":1360,"interventions":1363},"NCT03235973","Cladribine Dose Escalation in Conditioning Regimen Prior to Allo-HSCT for Refractory Acute Leukemia and Myelodysplastic Syndromes",[89],"2020-04","2021-04","2018-04-28",29,[1361,1362],"Leukemia, Myeloid, Acute","Leukemia, Lymphoblastic, Acute",[1346],{"trials":1365,"activeCount":100},[],{"trials":1367,"activeCount":100},[],{"trials":1369,"activeCount":100},[],{"trials":1371,"activeCount":100},[],{"intervention":1373,"totalTrials":168,"cells":1374},"HLA-mismatched microtransplantation",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1388,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1376,"activeCount":100},[],{"trials":1378,"activeCount":100},[1379],{"nctId":1380,"briefTitle":1381,"status":118,"phases":1382,"primaryCompletion":1383,"completion":1383,"start":1384,"enrollment":1385,"conditions":1386,"interventions":1387},"NCT03232268","HLA-mismatched Microtransplantation Without Immunosuppressive Treatment in Patients With Myeloid Hemopathies",[89],"2026-01-07","2018-03-09",25,[18,21],[1373],{"trials":1389,"activeCount":100},[],{"trials":1391,"activeCount":100},[],{"trials":1393,"activeCount":100},[],{"trials":1395,"activeCount":100},[],{"intervention":1397,"totalTrials":168,"cells":1398},"therapeutic autologous dendritic cells",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1411,"PHASE3":1413,"PHASE4":1415,"NA":1417},{"trials":1400,"activeCount":100},[],{"trials":1402,"activeCount":100},[1403],{"nctId":1404,"briefTitle":1405,"status":118,"phases":1406,"primaryCompletion":120,"start":1407,"enrollment":1408,"conditions":1409,"interventions":1410},"NCT00963521","Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission",[89],"2008-06",10,[27],[1397],{"trials":1412,"activeCount":100},[],{"trials":1414,"activeCount":100},[],{"trials":1416,"activeCount":100},[],{"trials":1418,"activeCount":100},[],{"intervention":1420,"totalTrials":168,"cells":1421},"BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide",{"EARLY_PHASE1":1422,"PHASE1":1424,"PHASE2":1435,"PHASE3":1437,"PHASE4":1439,"NA":1441},{"trials":1423,"activeCount":100},[],{"trials":1425,"activeCount":100},[1426],{"nctId":1427,"briefTitle":1428,"status":617,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":22,"conditions":1432,"interventions":1434},"NCT02487823","Dose Finding Study of BKM 120 in Combination With LH-RH Agonists and Bicalutamide in Men With Non Castrate Metastatic Prostate Cancer",[89],"2017-11","2014-10",[1433],"Non Castrate Metastatic Prostate Cancer",[1420],{"trials":1436,"activeCount":100},[],{"trials":1438,"activeCount":100},[],{"trials":1440,"activeCount":100},[],{"trials":1442,"activeCount":100},[],{"intervention":1444,"totalTrials":168,"cells":1445},"Vinorelbine, Cyclophosphamide and Interferon alpha 2b",{"EARLY_PHASE1":1446,"PHASE1":1448,"PHASE2":1459,"PHASE3":1461,"PHASE4":1463,"NA":1465},{"trials":1447,"activeCount":100},[],{"trials":1449,"activeCount":100},[1450],{"nctId":1451,"briefTitle":1452,"status":118,"phases":1453,"primaryCompletion":1316,"completion":120,"start":1454,"enrollment":1455,"conditions":1456,"interventions":1458},"NCT00908869","Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b (\" Metronomic Chemotherapy \") for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm",[89],"2006-05",30,[1457],"Advanced Neoplasm",[1444],{"trials":1460,"activeCount":100},[],{"trials":1462,"activeCount":100},[],{"trials":1464,"activeCount":100},[],{"trials":1466,"activeCount":100},[],{"intervention":1468,"totalTrials":168,"cells":1469},"Nab-paclitaxel + Gemcitabine",{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1483,"PHASE3":1485,"PHASE4":1487,"NA":1489},{"trials":1471,"activeCount":100},[],{"trials":1473,"activeCount":100},[1474],{"nctId":1475,"briefTitle":1476,"status":118,"phases":1477,"primaryCompletion":1478,"completion":1478,"start":1168,"enrollment":1479,"conditions":1480,"interventions":1482},"NCT02174887","Biological Effect of Nab-paclitaxel Combined to Gemcitabine in Metastatic Pancreatic Cancer",[89],"2016-10",19,[1481],"Pancreatic Adenocarcinoma",[1468],{"trials":1484,"activeCount":100},[],{"trials":1486,"activeCount":100},[],{"trials":1488,"activeCount":100},[],{"trials":1490,"activeCount":100},[],{"intervention":1492,"totalTrials":168,"cells":1493},"Monalizumab",{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1509,"PHASE3":1511,"PHASE4":1513,"NA":1515},{"trials":1495,"activeCount":100},[],{"trials":1497,"activeCount":100},[1498],{"nctId":1499,"briefTitle":1500,"status":147,"phases":1501,"primaryCompletion":1502,"completion":1503,"start":1504,"enrollment":1505,"conditions":1506,"interventions":1508},"NCT02921685","Study of a Humanized Antibody Initiated 2 Months After an HLA Matched Allogenic Stem Cell Transplantation",[89],"2019-05-28","2020-04-28","2016-11-28",18,[1507],"Hematologic Malignancies",[1492],{"trials":1510,"activeCount":100},[],{"trials":1512,"activeCount":100},[],{"trials":1514,"activeCount":100},[],{"trials":1516,"activeCount":100},[],{"intervention":1518,"totalTrials":168,"cells":1519},"NK Cell",{"EARLY_PHASE1":1520,"PHASE1":1522,"PHASE2":1533,"PHASE3":1535,"PHASE4":1537,"NA":1539},{"trials":1521,"activeCount":100},[],{"trials":1523,"activeCount":100},[1524],{"nctId":1525,"briefTitle":1526,"status":118,"phases":1527,"primaryCompletion":1528,"completion":1528,"start":1529,"enrollment":1530,"conditions":1531,"interventions":1532},"NCT01853358","Phase I of Infusion of Selected Donor NK Cells After Allogeneic Stem Cell Transplantation",[89],"2018-03-15","2013-04",17,[967],[1518],{"trials":1534,"activeCount":100},[],{"trials":1536,"activeCount":100},[],{"trials":1538,"activeCount":100},[],{"trials":1540,"activeCount":100},[],{"intervention":1542,"totalTrials":168,"cells":1543},"INA03 administration",{"EARLY_PHASE1":1544,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1566,"NA":1568},{"trials":1545,"activeCount":100},[1546],{"nctId":1547,"briefTitle":1548,"status":118,"phases":1549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":1169,"conditions":1553,"interventions":1559},"NCT03957915","Study of Escalating Doses of INA03 Administered Intravenously as Single Agent in Adult Patients With Relapse\u002FRefractory Acute Leukemia",[88],"2024-07-15","2025-02-24","2020-05-29",[1554,1555,1556,1557,1558],"Acute Lymphoblastic Leukemia Recurrent","Acute Lymphoblastic Leukemia, in Relapse","Acute Myeloid Leukemia, in Relapse","Acute Myeloid Leukaemia Recurrent","Mixed Phenotype Acute Leukemia",[1542],{"trials":1561,"activeCount":100},[],{"trials":1563,"activeCount":100},[],{"trials":1565,"activeCount":100},[],{"trials":1567,"activeCount":100},[],{"trials":1569,"activeCount":100},[],{"intervention":126,"totalTrials":645,"cells":1571},{"EARLY_PHASE1":1572,"PHASE1":1574,"PHASE2":1576,"PHASE3":1582,"PHASE4":1584,"NA":1586},{"trials":1573,"activeCount":100},[],{"trials":1575,"activeCount":100},[],{"trials":1577,"activeCount":100},[1578],{"nctId":116,"briefTitle":117,"status":118,"phases":1579,"primaryCompletion":120,"start":121,"enrollment":122,"conditions":1580,"interventions":1581},[89,90],[27],[125,96,126,127,128,129,130],{"trials":1583,"activeCount":100},[],{"trials":1585,"activeCount":100},[],{"trials":1587,"activeCount":100},[1588],{"nctId":1589,"briefTitle":1590,"status":118,"phases":1591,"primaryCompletion":120,"start":1592,"enrollment":621,"conditions":1593,"interventions":1594},"NCT00540956","Natural Killer Cells in Older Patients With Acute Myeloid Leukemia",[93],"2006-11",[27],[126],{"intervention":1596,"totalTrials":168,"cells":1597},"Constiutional DNA sampling",{"EARLY_PHASE1":1598,"PHASE1":1600,"PHASE2":1602,"PHASE3":1604,"PHASE4":1606,"NA":1608},{"trials":1599,"activeCount":100},[],{"trials":1601,"activeCount":100},[],{"trials":1603,"activeCount":100},[],{"trials":1605,"activeCount":100},[],{"trials":1607,"activeCount":100},[],{"trials":1609,"activeCount":100},[1610],{"nctId":1611,"briefTitle":1612,"status":147,"phases":1613,"primaryCompletion":1614,"completion":1614,"start":1615,"enrollment":1616,"conditions":1617,"interventions":1618},"NCT02619071","ChEmo-Genomics Based Treatment of Acute Myeloid Leukemia",[93],"2017-08","2015-08",87,[1361],[1596],{"intervention":1620,"totalTrials":168,"cells":1621},"molecular alteration",{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1626,"PHASE3":1628,"PHASE4":1630,"NA":1632},{"trials":1623,"activeCount":100},[],{"trials":1625,"activeCount":100},[],{"trials":1627,"activeCount":100},[],{"trials":1629,"activeCount":100},[],{"trials":1631,"activeCount":100},[],{"trials":1633,"activeCount":100},[1634],{"nctId":1635,"briefTitle":1636,"status":617,"phases":1637,"primaryCompletion":1638,"completion":1638,"start":1639,"enrollment":1640,"conditions":1641,"interventions":1642},"NCT01521676","Predictive Clinical and Biological Parameters in Breast Cancer",[93],"2026-01-15","2010-12-22",749,[15],[1620],{"intervention":1644,"totalTrials":168,"cells":1645},"administered therapeutic regimens",{"EARLY_PHASE1":1646,"PHASE1":1648,"PHASE2":1650,"PHASE3":1652,"PHASE4":1654,"NA":1656},{"trials":1647,"activeCount":100},[],{"trials":1649,"activeCount":100},[],{"trials":1651,"activeCount":100},[],{"trials":1653,"activeCount":100},[],{"trials":1655,"activeCount":100},[],{"trials":1657,"activeCount":100},[1658],{"nctId":1659,"briefTitle":1660,"status":118,"phases":1661,"primaryCompletion":1662,"completion":1662,"start":1663,"enrollment":1664,"conditions":1665,"interventions":1669},"NCT03469921","Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016",[],"2016-12-31","2000-01-01",602,[1666,29,1667,1668],"Malignant Haemopathies","Non-hodgkin Lymphoma","Hodgkin Lymphoma",[1644],{"intervention":1671,"totalTrials":168,"cells":1672},"genomic signature",{"EARLY_PHASE1":1673,"PHASE1":1675,"PHASE2":1677,"PHASE3":1679,"PHASE4":1681,"NA":1683},{"trials":1674,"activeCount":100},[],{"trials":1676,"activeCount":100},[],{"trials":1678,"activeCount":100},[],{"trials":1680,"activeCount":100},[],{"trials":1682,"activeCount":100},[],{"trials":1684,"activeCount":100},[1685],{"nctId":1686,"briefTitle":1687,"status":147,"phases":1688,"primaryCompletion":1689,"completion":1689,"start":164,"enrollment":1690,"conditions":1691,"interventions":1692},"NCT00912080","Utilization of Genomic Signature as Decision-making for Adjuvant Treatment of Breast Cancer",[93],"2015-05",375,[15],[1671],{"intervention":1694,"totalTrials":168,"cells":1695},"ibrutinib ou idelalisib",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1702,"PHASE4":1704,"NA":1706},{"trials":1697,"activeCount":100},[],{"trials":1699,"activeCount":100},[],{"trials":1701,"activeCount":100},[],{"trials":1703,"activeCount":100},[],{"trials":1705,"activeCount":100},[],{"trials":1707,"activeCount":100},[1708],{"nctId":1709,"briefTitle":1710,"status":147,"phases":1711,"primaryCompletion":1712,"completion":1712,"start":1713,"enrollment":621,"conditions":1714,"interventions":1716},"NCT03469895","Autoimmune Cytopenia and BcR Inhibitors",[],"2018-07","2017-07-21",[1715],"Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia",[1694],{"intervention":1718,"totalTrials":168,"cells":1719},"BRCA1 BRCA2 PTEN PALB2 mutation",{"EARLY_PHASE1":1720,"PHASE1":1722,"PHASE2":1724,"PHASE3":1726,"PHASE4":1728,"NA":1730},{"trials":1721,"activeCount":100},[],{"trials":1723,"activeCount":100},[],{"trials":1725,"activeCount":100},[],{"trials":1727,"activeCount":100},[],{"trials":1729,"activeCount":100},[],{"trials":1731,"activeCount":100},[1732],{"nctId":1733,"briefTitle":1734,"status":147,"phases":1735,"primaryCompletion":1736,"completion":1167,"start":1737,"enrollment":597,"conditions":1738,"interventions":1739},"NCT01434420","Triple Negative Breast Cancer: Study of Molecular and Genetic Factors",[93],"2014-08","2011-03",[15],[1718]]